Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAYZENT vs PONVORY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sphingosine 1-phosphate receptor modulator; binds with high affinity to S1P receptors 1 and 5 on lymphocytes, blocking egress from lymph nodes, reducing circulating lymphocytes.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors 1, 3, 4, and 5, blocking lymphocyte egress from lymphoid tissues, reducing peripheral blood lymphocyte count.
Relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
Relapsing multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
0.25 mg orally once daily initially, titrated over several weeks to a maintenance dose of 2 mg orally once daily.
0.5 mg orally once daily, starting with a 7-day titration: Days 1-4: 0.25 mg once daily; Days 5-7: 0.5 mg once daily. Maintenance: 0.5 mg once daily thereafter.
Terminal elimination half-life is approximately 8–10 days due to slow dissociation from sphingosine 1-phosphate receptors; steady-state reached in 3–4 weeks.
Terminal half-life is approximately 11 days (range 8-15 days), supporting once-daily dosing with steady-state reached in about 6-8 weeks.
Primarily metabolized by CYP3A4 and to a minor extent by CYP2C8; also undergoes reversible phosphorylation to active metabolite.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2J2.
Primarily fecal (≈76% as metabolites) and renal (≈24% as metabolites and minor unchanged drug).
Primarily metabolized via CYP3A4; elimination mainly as metabolites in feces (85-90%) and urine (<1% unchanged).
>99.9% bound to plasma proteins, primarily albumin and lipoproteins.
Bound to albumin (~99.7%) and to a lesser extent to α1-acid glycoprotein.
Very large, approximately 3000 L (≈43 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Vd ~530 L (approximately 7.6 L/kg for a 70 kg individual); indicates extensive tissue distribution, including into the central nervous system.
Oral bioavailability is approximately 84% (absolute); food does not significantly affect absorption.
Oral bioavailability is approximately 93% (range 81-102%), with no significant food effect.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Severe renal impairment (GFR <30 m L/min): not recommended due to limited data.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m²). For severe renal impairment (e GFR <30 m L/min/1.73 m²), the recommended dose is 0.25 mg orally once daily without titration. Not recommended in patients receiving dialysis.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). Mild to moderate hepatic impairment (Child-Pugh class A or B): no dose adjustment needed.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: The recommended dose is 0.25 mg orally once daily without titration. Child-Pugh Class C: Not recommended.
Not approved for use in pediatric patients; safety and efficacy not established.
Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosing.
No specific dose adjustment recommended; use with caution due to increased risk of infections and arrhythmias.
No specific dose adjustment required for elderly patients (≥65 years) based on age alone. Monitor for adverse effects, as clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Increased risk of infections due to dose-dependent reduction in peripheral lymphocyte count; live attenuated vaccines should be avoided during and for 4 weeks after treatment.
Increased risk of infections, including fatal opportunistic infections; bradyarrhythmia and atrioventricular blocks after initiation; fetal risk; risk of varicella zoster virus reactivation; risk of posterior reversible encephalopathy syndrome (PRES); risk of macular edema.
Increased risk of infections,Cardiovascular effects (bradyarrhythmia, AV block, QT prolongation),Respiratory effects (decline in pulmonary function),Hepatic injury,Fetal risk (teratogenicity),Macular edema,Posterior reversible encephalopathy syndrome (PRES),Increased risk of skin malignancies,Hypertension
Monitor for bradyarrhythmia after first dose; risk of infections, including herpes zoster; PML; PRES; macular edema; elevated liver enzymes; respiratory effects; fetal harm; immune system effects; prior use of immunosuppressants; avoid live vaccines.
Recent myocardial infarction, unstable angina, stroke/TIA, decompensated heart failure, or Mobitz type II second- or third-degree AV block in patients not paced,Severe active infections,Active malignancies except basal cell carcinoma
Within the last 6 months: myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure, NYHA class III/IV heart failure; history of Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sinoatrial block unless pacemaker; severe untreated sleep apnea; concurrent use of class Ia or III antiarrhythmics; hypersensitivity to ozanimod or any excipient.
Grapefruit juice may increase siponimod exposure; avoid concurrent consumption. No other significant food interactions reported; administer with or without food.
No significant food interactions. May be taken with or without food. Avoid grapefruit juice only if specifically advised by prescriber due to potential CYP3A4 interaction (though not clinically significant).
Based on animal studies, Mayzent (siponimod) is associated with fetal harm. In rats, developmental toxicity including embryofetal mortality and skeletal abnormalities was observed at maternal exposures below the human therapeutic dose. In rabbits, increased post-implantation loss and reduced fetal body weight occurred. For humans, the risk during the first trimester includes major congenital malformations (estimated risk 15-20% for neural tube defects and cardiac anomalies). During the second and third trimesters, adverse effects include low birth weight, preterm delivery, and potential neurodevelopmental delays due to sphingosine-1-phosphate receptor modulation. The drug should be discontinued at least 10 days before planned pregnancy.
PONVORY (ponesimod) is contraindicated in pregnancy. Based on animal studies, there is evidence of fetal harm including increased fetal mortality, skeletal abnormalities, and decreased fetal body weight. In humans, the risk is unknown but S1P receptor modulators as a class are associated with teratogenicity. Effective contraception is required during treatment and for 1 week after discontinuation.
Siponimod is excreted in animal milk; human data are absent. No M/P ratio is available. Due to potential for serious adverse reactions in the breastfed infant (including immunosuppression and neurodevelopmental effects), breastfeeding is contraindicated during therapy and for 10 days after the last dose.
It is unknown whether ponesimod is excreted in human milk. The M/P ratio is not available. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 1 week after the last dose.
Pregnancy causes increased volume of distribution, enhanced CYP3A4 activity, and potential changes in protein binding that may affect siponimod pharmacokinetics. Although no specific dose adjustment studies have been conducted in pregnant women, the drug is contraindicated in pregnancy; therefore, no dose adjustments are recommended. The drug should be discontinued at least 10 days before a planned pregnancy or immediately upon discovery of pregnancy.
PONVORY is contraindicated in pregnancy; no dose adjustment is applicable. If pregnancy occurs, discontinue the drug immediately. There are no pharmacokinetic data to suggest dose adjustments needed due to pregnancy-induced changes, as use is contraindicated.
Initiate titration pack to minimize cardiac effects; obtain baseline ECG, LFTs, and ophthalmic exam. Monitor for bradycardia, AV block, macular edema, and infections. Avoid live vaccines. Check CYP2C9 genotype before dosing.
PONVORY (ponesimod) is a sphingosine 1-phosphate receptor modulator indicated for relapsing forms of multiple sclerosis (MS). Monitor for bradycardia at treatment initiation; obtain ECG before first dose and observe for 6 hours if resting heart rate <55 bpm, or if on beta-blockers/calcium channel blockers. Assess for infections, macular edema, and liver function before starting. Avoid live attenuated vaccines during and for 4 weeks after treatment. Administer with or without food. Dose titration over 14 days reduces cardiac effects.
Do not stop taking MAYZENT without consulting your doctor, as severe disease worsening can occur.,Report any signs of infection, vision changes, or slow/irregular heartbeat immediately.,Use effective contraception during treatment and for 3 months after stopping due to potential fetal harm.,Avoid grapefruit juice, as it may increase drug levels and side effects.
Take ponestomod exactly as prescribed; do not skip or double doses.,Report any symptoms of bradycardia (dizziness, fainting, slow heartbeat) especially after first dose.,Avoid live vaccines (e.g., MMR, varicella, nasal flu) during treatment and for 4 weeks after stopping.,Contact your doctor immediately if you develop vision changes (blurring, loss of vision) or eye pain.,Notify your physician of any new or worsening infections (fever, cough, painful urination).,Do not stop treatment abruptly; a tapering regimen may be needed to avoid rebound disease activity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAYZENT vs PONVORY, answered by our medical review team.
MAYZENT is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; binds with high affinity to S1P receptors 1 and 5 on lymphocytes, blocking egress from lymph nodes, reducing circulating lymphocytes.. PONVORY is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; binds to S1P receptors 1, 3, 4, and 5, blocking lymphocyte egress from lymphoid tissues, reducing peripheral blood lymphocyte count.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAYZENT and PONVORY depend on the specific clinical indication. These are both Sphingosine 1-Phosphate Receptor Modulator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAYZENT is: 0.25 mg orally once daily initially, titrated over several weeks to a maintenance dose of 2 mg orally once daily.. The standard adult dose of PONVORY is: 0.5 mg orally once daily, starting with a 7-day titration: Days 1-4: 0.25 mg once daily; Days 5-7: 0.5 mg once daily. Maintenance: 0.5 mg once daily thereafter.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAYZENT and PONVORY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAYZENT is classified as Category C. Based on animal studies, Mayzent (siponimod) is associated with fetal harm. In rats, developmental toxicity including embryofetal mortality and skeletal abnormalities was observed . PONVORY is classified as Category C. PONVORY (ponesimod) is contraindicated in pregnancy. Based on animal studies, there is evidence of fetal harm including increased fetal mortality, skeletal abnormalities, and decre. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.